Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
4
80%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

completed240%
unknown120%
withdrawn240%

Recent Activity

0 active trials
Showing 5 of 5
withdrawnphase_1

Dendritic Cell Vaccine to Prevent COVID-19

NCT07501208
withdrawnphase_1

Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults

NCT04386252
completedphase_1

Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection

NCT04690387
completedphase_2

Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19

NCT05007496
unknownphase_1

Dendritic Cell Vaccine to Prevent COVID-19

NCT04685603

Clinical Trials (5)

Showing 5 of 5 trials
NCT07501208Phase 1

Dendritic Cell Vaccine to Prevent COVID-19

Withdrawn
NCT04386252Phase 1

Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults

Withdrawn
NCT04690387Phase 1

Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection

Completed
NCT05007496Phase 2

Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19

Completed
NCT04685603Phase 1

Dendritic Cell Vaccine to Prevent COVID-19

Unknown

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5